Khiron Life Sciences Corporation (TSXV: KHRN)(OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated international cannabis leader with core operations in and , has announced that the company presented results from its first research study including 1,453 patients from Khiron-subsidiary Zerenia Clinics at the 29th International Pain Conference in Barranquilla, , organized by ACED, the Colombian chapter of the International Association for the Study of Pain (IASP).
“Scientific research and data are key to convincing doctors and policy makers all over the world about the benefits of medical cannabis to treat conditions that are prevalent in every society and market we are targeting. After one year of compiling information and having gone through a very detailed approval process, we are very proud to share the results from this first-of-its-kind clinical study in Latin America with such a significant patient base,” said Khiron CEO Álvaro Torres.
“This is just the beginning of our ongoing research program. We are looking forward to sharing the outcomes of this first cohort study with the international medical audience through peer-reviewed, specialized publications so doctors all over the world can continue to drive prescription growth safely and responsibly,” added Torres.